|
Sep 28
|
Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now
|
|
Sep 25
|
Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges
|
|
Jun 27
|
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
|
|
May 11
|
Coherus BioSciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
May 10
|
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 9
|
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 9
|
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
|
|
May 8
|
When Can We Expect A Profit From Coherus BioSciences, Inc. (NASDAQ:CHRS)?
|
|
May 8
|
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
|
|
May 1
|
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
|
|
Apr 24
|
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
Apr 11
|
Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 83% over the last five years
|
|
Apr 8
|
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
|
|
Mar 16
|
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript
|
|
Mar 15
|
Coherus BioSciences Full Year 2023 Earnings: EPS Misses Expectations
|
|
Mar 14
|
Why Coherus Biosciences Stock Tumbled on Thursday
|
|
Mar 14
|
Q4 2023 Coherus BioSciences Inc Earnings Call
|
|
Mar 13
|
Coherus BioSciences Inc (CHRS) Reports Growth in Net Revenue for Q4 and Full Year 2023 Despite ...
|
|
Mar 13
|
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
|